A. Deschildre and M. André, Indications et conduite du traitement de l???infection tuberculeuse latente (ITL), Revue des Maladies Respiratoires, vol.25, issue.6, 2008.
DOI : 10.1016/S0761-8425(08)56018-9

M. Paty, L'organisation de la lutte antituberculeuse et la mise en oeuvre du programme de lutte contre la tuberculose en France, INVS, pp.12-13

. Meta, New tests for the Diagnosis of the Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research, Ann Intern Med, vol.146, pp.340-354, 2007.

H. Simsek, S. Alpar, N. Uçar, F. Aksu, I. Ceyhan et al., Comparison of Tuberculin skin Testing and T-SPOT.TB for Diagnosis of Latent and Active Tuberculosis, Jpn. J. Infect. Dis, vol.63, pp.99-102, 2010.

. Meta, New tests for the Diagnosis of the Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research, Ann Intern Med, vol.146, pp.340-354, 2007.

J. Lighter, M. Rigaud, R. Eduardo, C. Peng, and H. Pollack, Latent Tuberculosis Diagnosis in Children by Using the QuantiFERON-TB Gold In-Tube Test, PEDIATRICS, vol.123, issue.1, pp.30-37, 2009.
DOI : 10.1542/peds.2007-3618

M. Benjamin, K. Smith, M. Schwartzman, G. Mph, P. Bartlett et al., Adverse events associated with treatment of latent tuberculosis in the general population, CMAJ, vol.183, issue.3, 2011.

F. Fahmi-yousef-khan and . Rassoul, Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review, Indian Journal of Critical Care Medicine, vol.14, issue.2, pp.97-100, 2010.
DOI : 10.4103/0972-5229.68226

M. Morbidity and . Weekly-report, Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for latent Tuberculosis Infection-United States, 2004.

M. Natacha, Traitement de la tuberculose sans prévue bactériologique: évaluation de la réponse au traitement et recherche des facteurs prédictifs de réponse

C. , R. Horsburgh, S. Jr, J. Goldberg, S. Bethel et al., Paul Weinfurter and the Tuberculosis Epidemiologic Studies Consortium. Latent TB infection treatment acceptance and completion in the United States and Canada, Chest, vol.137, pp.401-409, 2010.

L. Jiehui, S. S. Munsiff, T. Tarantino, and M. Dorsinville, Adherance to treatment of latent tuberculosis infection in a clinical population in New York City, International Journal of infection diseases, vol.14, pp.292-297, 2010.

J. Ena and V. Valls, Short-Course Therapy with Rifampin plus Isoniazid, Compared with Standard Therapy with Isoniazid, for Latent Tuberculosis Infection: A Meta-analysis, Clinical Infectious Diseases, vol.40, issue.5, pp.670-676, 2005.
DOI : 10.1086/427802

M. Hovell, Multi-Level Barriers to Latent Tuberculosis Infection Treatment: A research Note, J Immigrant Minority Health, vol.12, pp.544-550, 2010.

J. David and . Gerberry, Trade-off between BCG vaccination and the ability to detect and treat latent tuberculosis, Journal of Theoretical Biology, vol.261, pp.548-560, 2009.

D. Bruhl and . Che, Couverture vaccinale par le BCG et épidémiologie de la tuberculose chez l'enfant : où en est-on un an après la levée de l'obligation vaccinale en France, INVS, pp.12-13